STEEPER
1.9.2021 13:09:04 CEST | Business Wire | Press release
In their centenary year Steeper Group, a world leading manufacturer of prosthetic devices, launch their latest myoelectric system. The full limb build is designed to offer patients and clinicians across the globe a durable, high-capacity upper limb system at an affordable cost, which harnesses the power of popular myoelectric technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005522/en/
Designed for the everyday, the Steeper Myoelectric System includes the new Myo Kinisi hand which provides an easy to control, high-speed grasp alongside a strong grip force to carry out activities of daily living with ease, with the added benefit of an Auto-Grip function allowing users a more secure grip on difficult to hold objects. The hand is complemented by advanced myoelectrodes for increased accuracy and gain control, and is powered by the all new high-capacity S-Charge System which features a 3500mAh internal battery, making it one of the most powerful available. The prosthesis is finished by the ‘Elegance Plus’ cosmetic glove, designed specifically to complement the Myo Kinisi.
Paul Steeper, CEO of Steeper Group and SteeperUSA commented “a new myoelectric system is something our customers have desired for some time. We’ve used our innovative knowledge of upper limb prostheses to deliver an evolution to a myoelectric system; using the latest advancements in product design, super capacitor technology and modern materials such as titanium for increased strength.”
Patients will enjoy the enhanced cosmesis given by the Elegance Plus silicone glove which has been designed to work in harmony with the Myo Kinisi. An internal reinforced mesh layer increases durability for even high activity users, and improved realism to the skin appearance is achieved with enhancement on the knuckles, joints and nail finish; the Elegance Plus Glove is available in 19 TrueFinishTM shades.
Clinicians can program the Myo Kinisi to meet exacting patient preferences with a choice of five modes and fine adjustments to control parameters can be made via the Steeper Configuration Device, a simple three button operation programming hub with an easy-to-read screen.
Paul Steeper concluded “the Steeper Myoelectric System will offer both clinicians and users a greater choice of durable, reliable and easy to use devices. The Myo Kinisi offers superb grip strength via trusted technology and the Elegance Plus Glove is sure appeal to a wide range of users with its enhanced finish and skin-like texture; couple that with our very latest myoelectrodes and increased capacity S-Charge battery system and users will instantly benefit from these innovations. Patient trials have proved successful with users commenting on the increased control the Myo Kinisi offers whilst using a control strategy they are already familiar with; meaning the hand is easily and readily usable.”
ENDS
Notes to editors:
Steeper Group trade as SteeperUSA within the United States and Canada.
For more information on the Steeper Myoelectric System or any of our upper limb prosthetic products, please visit www.steepergroup.com or www.steeperusa.com .
Image caption: The Steeper Upper Limb Build offers a secure grip, an enhanced cosmetic appearance and is powered by one of the most powerful battery systems on the market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005522/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom